Major Depressive DisorderNCT05598034
Evaluating tDCS Brain-stimulation in Depression Using MRI
A study testing Left DLPFC tDCS, Right DLPFC tDCS and Cognitive task in people with Major Depressive Disorder, run by University of California, Los Angeles at 1 site in United States.
Trial summary
Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific scalp locations and… Read more about this study
- Who is it for?
- Ages 20 to 55 years
- Conditions the study is for
- Major Depressive Disorder
- What is being tested?
- Left DLPFC tDCS, Right DLPFC tDCS and Cognitive task
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 144 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Oct 2022to 1 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age between 20 to 55 years, inclusive
- Gender: all
- Race/ethnicity: all races and ethnic groups
- Capacity to provide informed consent
- Hamilton Rating Scale for Depression score of ≥17 and <24, with or without symptoms of anxiety.
- Treatment naïve or on a stable standard antidepressant regimen (including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MOAIs) or tricyclic's (TCAs)) with no change in treatment 6-weeks prior to and during the tDCS intervention.
- Work at UCLA or live within 1-hr driving distance of UCLA
Who cannot join
- Pregnancy
- Non-English speaking (due to scales administered)
- Substance Use Disorder within last 12 months
- Neurological condition associated with brain abnormalities (e.g., traumatic brain injury; recent stroke, tumor)
- Any contraindication to tDCS (e.g., skin disease or treatment causing irritation)
- Any condition that would contraindicate scanning (metal implants, claustrophobia or a breathing or movement disorder)
Show all 16Show fewer
- Currently receiving any form of psychotherapy
- Change in antidepressant medication within 6-weeks of starting the trial
- Severe or treatment resistant depression - HAMD scores > 24 and a history of a major depressive episode lasting >2- years or failure to 2 or more antidepressant trials in the current index episode
- Any neuromodulation therapy (e.g., ECT, rTMS, DBS, VNS or tDCS) within the last 3-months
- Current or past (within the last 1-month) use of anticonvulsants, lithium, psychostimulant, dexamphetamine
- Current use of decongestants or other medication previously shown to interfere with cortical excitability
- Diagnosis: Schizophrenia Axis I disorder, or dementia of any type
- Bipolar I disorder (due to possible risk of mania and because lithium and anticonvulsants are excluded).
- On regular benzodiazepine medication that it is not clinically appropriate to discontinue for the 2-week duration of the trial
- Depression related to serious medical illness (i.e., mood disorder due to general medical condition) 17. Actively suicidal as defined by a score of 4 on item 3 of HAMD
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of California Los Angeles (UCLA)
Los Angeles, California, 90095
Mayank A Jog, PhD, 4242886483, brainmapping.ucla@gmail.com
About this study
Official title: Optimization of tDCS Brain Network Engagement in Depression
Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific scalp locations and using a 9-volt battery to cause a small amount of electricity to pass through parts of the brain. Depending on the direction of electrical flow, tDCS can make brain cells (neurons) more likely or less likely to generate their own electrical signals. When evaluated as a treatment, tDCS is typically done in daily sessions over a period of two weeks.
One of the challenges of tDCS is to work out the best possible positioning of electrodes and direction of electricity flow to gradually cause lasting changes in brain activity in ways that might be expected to improve depression. To address this challenge, the investigators are using MRI to take pictures of the brain during tDCS. This data will help us better understand the short-term effects of tDCS in depression and help us learn how to customize future treatments to cause a lasting beneficial response.
Read more
Patients with depression between the ages of 20-55 years are eligible to take part in this research. Potential participants will undergo:
- An assessment to confirm eligibility. This will take place over a secure videoconference call lasting no more than 3 hours.
- Two in-person study visits lasting 30 min and 2-1/2 hours respectively. In the first visit, the investigators will use the MRI to take a picture of the brain and head structure to determine appropriate locations for placing the tDCS electrodes at the start of the second visit. Following electrode placement, an MRI scan will be performed to take pictures of the brain during tDCS. Depending on the study arm,
- Participants may receive 'active' or 'sham' tDCS. The 'sham' condition is identical to the 'active' tDCS in every way except that it involves minimal tDCS and is designed to help rule out effects unrelated to the administered tDCS electricity.
- Participants may also be asked to perform a mental task during MRI.
Read the detailed description
Depression is characterized by disruption in the regulation of emotion and mood. Converging evidence from multiple brain imaging studies indicates that depression is associated with dysfunction in the top-down, emotion-regulating frontoparietal brain regions that include the hypoactive left dorsolateral prefrontal cortex (DLPFC) brain region and the hyperactive right DLPFC. Dysfunction in additional brain regions including the cingulate cortex, hippocampus and amygdala has also been linked to depressive symptoms. Together, these brain regions form the dorso-fronto-limbic brain network, and beneficial modulation of this specific network has been hypothesized to improve depressive symptoms.
Network modulation is feasible using a wide range of brain stimulation techniques, including transcranial direct current stimulation (tDCS). The latter technique has recently received high interest in the context of moderate depression due to its demonstrated safety, low-cost and non-invasive nature. A typical tDCS setup consists of non-invasive electrodes placed on the scalp to administer tolerable electric currents at specific brain targets. The administered electric current has been shown to modulate brain activity depending on the direction of the applied electricity, with anodal tDCS increasing neuronal activity at the brain-target, and cathodal tDCS decreasing activity at the targeted brain region. Consequently, tDCS setups in depression have typically targeted the aforementioned hypoactive left DLPFC using anodal tDCS and/or the hyperactive right DLPFC using cathodal tDCS. However, the downstream effects of tDCS on the dorso-fronto-limbic network are not fully understood. Understanding the engagement of this depression-relevant brain network by tDCS could provide important insights into optimizing tDCS setups for antidepressant applications. Consequently, the current study is proposing to use MRI techniques to map and investigate network engagement by tDCS in depression, as described below. Note that while Study arm 1 will use data from an existing study, arms 2-4 will involve recruitment of depressed participants de-novo.
- Study arm 1 will investigate the engagement of the dorso-fronto-limbic brain network in depression when 'active' or 'sham' anodal tDCS is administered at the left DLPFC brain region at rest. 'Sham' tDCS provides a control condition to facilitate the measurement of tDCS-specific effects, and besides involving minimal electricity, is designed to be identical to 'active' tDCS in every other way (e.g. electrode placement, etc.). For this arm, de-identified data from an ongoing clinical trial in depression with separate aims will be acquired for analysis (NCT04507243, N=48 participants, randomized to 24 'active' and 24 'sham' groups).
- Study arm 2 will investigate network engagement when anodal tDCS is administered at the left DLPFC brain region during the performance of a mental task (2-back working memory). N=24 subjects will be enrolled using a single group experimental design incorporating a within-session control condition (instead of a separate 'sham' group as in Arm 1). Participation will involve one assessment over a secure videoconference call to confirm eligibility (lasting no more than 3 hours), and two in-person study visits (lasting 30 min and 2.5 hours respectively). Both in-person visits will involve MRI's: the first visit's MRI scans will help determine tDCS electrode positioning for the second visit, and the second visit's MRI scans will help us map changes in brain activity and connectivity during tDCS.
- Study arms 3 and 4 will investigate network engagement during right DLPFC cathodal tDCS. N=48 participants will be recruited for arm 3 (randomized to 24 'active' and 24 'sham') and N=24 participants will be recruited for arm 4. In all other respects, study arms 3 and 4 will be identical to study arms 1 and 2 respectively.
- Conditions
- Major Depressive Disorder
- Being tested
- Left DLPFC tDCS, Right DLPFC tDCS, Cognitive task
- Keywords
- Transcranial Direct Current Stimulation (tDCS), MRI, Major Depression
- Medical subject headings
- Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Left DLPFC tDCSDevice
This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
Right DLPFC tDCSDevice
This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
Cognitive taskBehavioural
Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
| Study group | Role | What they receive |
|---|---|---|
| Left DLPFC tDCS | Experimental | Participants randomized to this arm will receive tDCS at the left DLPFC brain region. Receives: Device: Left DLPFC tDCS |
| Left DLPFC tDCS + task | Experimental | Participants randomized to this arm will receive tDCS at the left DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time. Receives: Device: Left DLPFC tDCS; Behavioral: Cognitive task |
| Right DLPFC tDCS | Experimental | Participants randomized to this arm will receive tDCS at the right DLPFC brain region. Receives: Device: Right DLPFC tDCS |
| Right DLPFC tDCS + task | Experimental | Participants randomized to this arm will receive tDCS at the right DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time. Receives: Device: Right DLPFC tDCS; Behavioral: Cognitive task |
What is being measured
The primary outcome is the main question the study is designed to answer.
Activity changes in the dorso-fronto-limbic brain network
fMRI-BOLD signal within nodes of the dorso-fronto-limbic brain network will be analyzed for activity changes concurrent with tDCS
Measured: Within the 2.5 hour fMRI session
Secondary outcomes (1)
Connectivity changes in the dorso-fronto-limbic brain network
fMRI-BOLD signal within nodes of the dorso-fronto-limbic brain network will be analyzed for connectivity changes occuring with tDCS
Measured: Within the 2.5 hour fMRI session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2022
- Study start20 Oct 2022
- Primary completion1 Apr 2028 (estimated)
- Study completion1 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Major Depressive DisorderStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 144 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, Mayank Anant Jog, University of California, Los Angeles
- Investigators
- Mayank A Jog, PhD, Principal investigator, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05598034
- Sponsor's protocol ID
- MH128572
- Other IDs
- K99MH128572
- Status last verified
- Jun 2026
- First submitted
- 21 Oct 2022
- Last updated
- 8 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimization of tDCS Brain Network Engagement in Depression
- ClinicalTrials.gov ID
- NCT05598034
- Acronym / sponsor ID
- MH128572
- Conditions
- Major Depressive Disorder
- Keywords
- Transcranial Direct Current Stimulation (tDCS), MRI, Major Depression
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 144 participants (estimated)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- 20 Oct 2022 (actual)
- Primary completion
- 1 Apr 2028 (estimated)
- Study completion
- 1 May 2028 (estimated)
- First posted
- 28 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific scalp locations and using a 9-volt battery to cause a small amount of electricity to pass through parts of the brain. Depending on the direction of electrical flow, tDCS can make brain cells (neurons) more likely or less likely to generate their own electrical signals. When evaluated as a treatment, tDCS is typically done in daily sessions over a period of two weeks.
One of the challenges of tDCS is to work out the best possible positioning of electrodes and direction of electricity flow to gradually cause lasting changes in brain activity in ways that might be expected to improve depression. To address this challenge, the investigators are using MRI to take pictures of the brain during tDCS. This data will help us better understand the short-term effects of tDCS in depression and help us learn how to customize future treatments to cause a lasting beneficial response.
Patients with depression between the ages of 20-55 years are eligible to take part in this research. Potential participants will undergo:
- An assessment to confirm eligibility. This will take place over a secure videoconference call lasting no more than 3 hours.
- Two in-person study visits lasting 30 min and 2-1/2 hours respectively. In the first visit, the investigators will use the MRI to take a picture of the brain and head structure to determine appropriate locations for placing the tDCS electrodes at the start of the second visit. Following electrode placement, an MRI scan will be performed to take pictures of the brain during tDCS. Depending on the study arm,
- Participants may receive 'active' or 'sham' tDCS. The 'sham' condition is identical to the 'active' tDCS in every way except that it involves minimal tDCS and is designed to help rule out effects unrelated to the administered tDCS electricity.
- Participants may also be asked to perform a mental task during MRI.
Detailed description
Depression is characterized by disruption in the regulation of emotion and mood. Converging evidence from multiple brain imaging studies indicates that depression is associated with dysfunction in the top-down, emotion-regulating frontoparietal brain regions that include the hypoactive left dorsolateral prefrontal cortex (DLPFC) brain region and the hyperactive right DLPFC. Dysfunction in additional brain regions including the cingulate cortex, hippocampus and amygdala has also been linked to depressive symptoms. Together, these brain regions form the dorso-fronto-limbic brain network, and beneficial modulation of this specific network has been hypothesized to improve depressive symptoms.
Network modulation is feasible using a wide range of brain stimulation techniques, including transcranial direct current stimulation (tDCS). The latter technique has recently received high interest in the context of moderate depression due to its demonstrated safety, low-cost and non-invasive nature. A typical tDCS setup consists of non-invasive electrodes placed on the scalp to administer tolerable electric currents at specific brain targets. The administered electric current has been shown to modulate brain activity depending on the direction of the applied electricity, with anodal tDCS increasing neuronal activity at the brain-target, and cathodal tDCS decreasing activity at the targeted brain region. Consequently, tDCS setups in depression have typically targeted the aforementioned hypoactive left DLPFC using anodal tDCS and/or the hyperactive right DLPFC using cathodal tDCS. However, the downstream effects of tDCS on the dorso-fronto-limbic network are not fully understood. Understanding the engagement of this depression-relevant brain network by tDCS could provide important insights into optimizing tDCS setups for antidepressant applications. Consequently, the current study is proposing to use MRI techniques to map and investigate network engagement by tDCS in depression, as described below. Note that while Study arm 1 will use data from an existing study, arms 2-4 will involve recruitment of depressed participants de-novo.
- Study arm 1 will investigate the engagement of the dorso-fronto-limbic brain network in depression when 'active' or 'sham' anodal tDCS is administered at the left DLPFC brain region at rest. 'Sham' tDCS provides a control condition to facilitate the measurement of tDCS-specific effects, and besides involving minimal electricity, is designed to be identical to 'active' tDCS in every other way (e.g. electrode placement, etc.). For this arm, de-identified data from an ongoing clinical trial in depression with separate aims will be acquired for analysis (NCT04507243, N=48 participants, randomized to 24 'active' and 24 'sham' groups).
- Study arm 2 will investigate network engagement when anodal tDCS is administered at the left DLPFC brain region during the performance of a mental task (2-back working memory). N=24 subjects will be enrolled using a single group experimental design incorporating a within-session control condition (instead of a separate 'sham' group as in Arm 1). Participation will involve one assessment over a secure videoconference call to confirm eligibility (lasting no more than 3 hours), and two in-person study visits (lasting 30 min and 2.5 hours respectively). Both in-person visits will involve MRI's: the first visit's MRI scans will help determine tDCS electrode positioning for the second visit, and the second visit's MRI scans will help us map changes in brain activity and connectivity during tDCS.
- Study arms 3 and 4 will investigate network engagement during right DLPFC cathodal tDCS. N=48 participants will be recruited for arm 3 (randomized to 24 'active' and 24 'sham') and N=24 participants will be recruited for arm 4. In all other respects, study arms 3 and 4 will be identical to study arms 1 and 2 respectively.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Left DLPFC tDCS | Experimental | Device: Left DLPFC tDCSParticipants randomized to this arm will receive tDCS at the left DLPFC brain region. |
| Left DLPFC tDCS + task | Experimental | Device: Left DLPFC tDCS, Behavioral: Cognitive taskParticipants randomized to this arm will receive tDCS at the left DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time. |
| Right DLPFC tDCS | Experimental | Device: Right DLPFC tDCSParticipants randomized to this arm will receive tDCS at the right DLPFC brain region. |
| Right DLPFC tDCS + task | Experimental | Device: Right DLPFC tDCS, Behavioral: Cognitive taskParticipants randomized to this arm will receive tDCS at the right DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time. |
Who may qualify
- Ages
- 20 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Age between 20 to 55 years, inclusive
- Gender: all
- Race/ethnicity: all races and ethnic groups
- Capacity to provide informed consent
- Hamilton Rating Scale for Depression score of ≥17 and <24, with or without symptoms of anxiety.
Key exclusion criteria (16 listed)
- Pregnancy
- Non-English speaking (due to scales administered)
- Substance Use Disorder within last 12 months
- Neurological condition associated with brain abnormalities (e.g., traumatic brain injury; recent stroke, tumor)
- Any contraindication to tDCS (e.g., skin disease or treatment causing irritation)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Left DLPFC tDCSThis intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current. | Device | Left DLPFC tDCS, Left DLPFC tDCS + task |
| Right DLPFC tDCSThis intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current. | Device | Right DLPFC tDCS, Right DLPFC tDCS + task |
| Cognitive taskParticipants will be asked to perform a 2-back working memory mental task alongside administered tDCS | Behavioural | Left DLPFC tDCS + task, Right DLPFC tDCS + task |
Primary outcome
Activity changes in the dorso-fronto-limbic brain network
Time frame: Within the 2.5 hour fMRI session
fMRI-BOLD signal within nodes of the dorso-fronto-limbic brain network will be analyzed for activity changes concurrent with tDCS
1 secondary outcome
Connectivity changes in the dorso-fronto-limbic brain network
Time frame: Within the 2.5 hour fMRI session
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Major Depressive Disorder
Active, not recruitingPhase 4
Neural Circuit Effects of Ketamine in Depression
Major Depressive Disorder
Active, not recruiting
rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression
Depression, Treatment Resistant
Recruiting
Peer-Delivered Behavioral Activation in a CCBHC
Major Depressive Disorder, Substance Use Disorders
RecruitingPhase 3
Efficacy of Statins Among Major Depressive Disorder
Major Depressive Disorder, MDD
Recruiting
IMST for Dementia Risk Reduction
Systolic Blood Pressure, Blood Pressure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mayank A Jog, PhD principal investigator
University of California, Los Angeles
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Left DLPFC tDCS, Right DLPFC tDCS and Cognitive task in people with Major Depressive Disorder, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mayank A Jog, PhD (424-288-6483, brainmapping.ucla@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Activity changes in the dorso-fronto-limbic brain network (time frame: Within the 2.5 hour fMRI session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.